Quantcast
Home / Opinion Digests / Securities – Securities Fraud – Experimental Drug Prospects (access required)

Securities – Securities Fraud – Experimental Drug Prospects (access required)

Disappointed investors cannot state a claim for securities fraud against a pharmaceutical company that allegedly overstated the prospects for an experimental drug the company was developing to treat dry eye disease; the 4th Circuit says that judged by the standard of the Private Securities Litigation Reform Act of 1995 and by Tellabs Inc. v. Makor ...

Leave a Reply